Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
暂无分享,去创建一个
Michael Peyton | Humam Kadara | Murim Choi | Pan Tong | John N Weinstein | Gordon B Mills | John V Heymach | Kevin R Coombes | Lixia Diao | Jing Wang | Kwok-Kin Wong | Luc Girard | Roy S Herbst | Youhong Fan | Andrew Futreal | Timothy P Heffernan | Maria A Cortez | Uma Giri | Jianjun Zhang | Waun K Hong | Vincent Miller | Carmen Behrens | Ignacio I Wistuba | John D Minna | J. Weinstein | K. Coombes | G. Mills | Jing Wang | J. Minna | W. Hong | I. Wistuba | L. Girard | Kwok-Kin Wong | M. Peyton | P. Sharma | R. Herbst | V. Miller | G. Frampton | J. Allison | C. Behrens | Murim Choi | Jianhua Zhang | L. Byers | A. Futreal | V. Papadimitrakopoulou | P. Tong | T. Heffernan | C. Toniatti | J. Izzo | L. Diao | Jianjun Zhang | U. Giri | M. Cortez | Youhong Fan | E. Parra | F. Skoulidis | Padmanee Sharma | Carlo Toniatti | Vassiliki A Papadimitrakopoulou | H. Kadara | Garrett M Frampton | Lauren A Byers | Jianhua Zhang | J. Gudikote | James P Allison | Ferdinandos Skoulidis | Jayanthi Gudikote | Jaime Rodriguez Canales | Julie Izzo | Edwin R Parra | Chao Yang | Chaoxu Yang | J. Canales | J. Heymach | Kwok-kin Wong | W. Hong | J. R. Canales | Padmanee Sharma
[1] Chris Sander,et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.
[2] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[3] Qun Zhou,et al. miR-200a Regulates Nrf2 Activation by Targeting Keap1 mRNA in Breast Cancer Cells* , 2011, The Journal of Biological Chemistry.
[4] I. Tikhonova,et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing , 2009, Proceedings of the National Academy of Sciences.
[5] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[6] L. Neckers,et al. Heat Shock Protein 90 Modulates the Unfolded Protein Response by Stabilizing IRE1α , 2002, Molecular and Cellular Biology.
[7] References , 1971 .
[8] Takeshi Nagayasu,et al. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. , 2012, The Journal of clinical investigation.
[9] T. Boggon,et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma , 2013, Proceedings of the National Academy of Sciences.
[10] L. Girard,et al. Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis , 2014, Molecular Cancer Research.
[11] John V Heymach,et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.
[12] M. Ladanyi,et al. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma , 2013, Modern Pathology.
[13] Igor Jurisica,et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Doebele,et al. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. , 2014, Seminars in oncology.
[15] Michael Peyton,et al. Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.
[16] D. Carbone,et al. LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] I. Wistuba,et al. EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma , 2013, Clinical Cancer Research.
[18] L. Tsai,et al. The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss , 2014, Oncogene.
[19] Takla Griss,et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α , 2014, Proceedings of the National Academy of Sciences.
[20] Patricia Greninger,et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.
[21] S. Mane,et al. K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.
[22] M. Meyerson,et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. , 2013, Molecular cell.
[23] Travis J Cohoon,et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. , 2013, Cancer discovery.
[24] Navdeep S. Chandel,et al. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.
[25] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[26] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[27] I. Mills,et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. , 2012, The Journal of clinical investigation.
[28] G. Mills,et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS , 2010, Proceedings of the National Academy of Sciences.
[29] P. Jänne,et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Michael Peyton,et al. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.
[31] J. Minna,et al. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients , 2013, Clinical Cancer Research.
[32] Aimee L Jackson,et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.
[33] D. Ross,et al. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. , 2012, Biochemical pharmacology.
[34] M. Wilkerson,et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.
[35] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] L. Girard,et al. Oncogenes and Tumor Suppressors Nullifying the CDKN 2 AB Locus Promotes Mutant Kras Lung Tumorigenesis , 2014 .
[37] Lixia Diao,et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.
[38] T. Stinchcombe,et al. MEK inhibition in non-small cell lung cancer. , 2014, Lung cancer.
[39] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[40] S. Quezada,et al. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication , 2011, Immunological reviews.
[41] Lucio Crinò,et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.
[42] Andrew L. Kung,et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.
[43] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[44] D. Hayes,et al. The LKB1 Tumor Suppressor as a Biomarker in Mouse and Human Tissues , 2013, PloS one.
[45] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[46] L. Neckers,et al. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. , 2002, Molecular and cellular biology.
[47] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[48] K. Coombes,et al. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). , 2013 .
[49] P. Jänne,et al. The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.
[50] Shuji Ogino,et al. Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.
[51] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[52] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[53] E. Dmitrovsky,et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.
[54] Pablo Tamayo,et al. Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[55] Alan R. Dabney. ClaNC: point-and-click software for classifying microarrays to nearest centroids , 2006, Bioinform..
[56] D. Esposito,et al. Dragging ras back in the ring. , 2014, Cancer cell.
[57] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[58] Z. Szallasi,et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.
[59] J. Engelman,et al. ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Renaud Gaujoux,et al. A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.
[61] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.